公开(公告)号：EP1669450A1

公开(公告)日：2006-06-14

申请号：EP04788459.8

申请日：2004-09-29

申请人： AnGes MG, Inc.

发明人： KUNUGIZA, Yasuo ,  TOMITA, Naruya ,  HASHIMOTO, Hideo ,  YOSHIKAWA, Hideki ,  MORISHITA, Ryuichi

IPC分类号： C12N15/11 ,  A61K48/00 ,  A61K31/713 ,  A61P37/00 ,  A61P17/00 ,  A61P9/00 ,  A61P13/10 ,  A61P13/12 ,  A61P13/08 ,  A61P13/02 ,  A61P1/04

CPC分类号： A61K31/713 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/51

摘要： Conventional oligonucleotides are opened at both ends and thereby unstable. The stability of them against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides a staple oligonucleotides and medicaments containing the same as the active ingredient. Specifically, it provides transcription factor inhibitors, antisense oligonucleotides and siRNAs. More specifically, it provides agents for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischaemic diseases, worsened prognosis after organ transplantation or organ surgery, or restenosis after PTCA. Further specifically, it provides agents for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn disease, chronic rheumatoid arthritis, osteoarthritis, atopic dermatitis, contact dermatitis, psoriasis, cutaneous ulcer or decubitus.

摘要翻译： 常规寡核苷酸在两端开放，从而不稳定。 它们对分解代谢酶的稳定性被硫代磷酸酯修饰增加，但是这种硫代磷酸酯引起毒性。 本发明提供了改善这些问题的寡核苷酸和药物。 也就是说，它提供了含有与活性成分相同的主要的寡核苷酸和药物。 具体地，它提供转录因子抑制剂，反义寡核苷酸和siRNA。 更具体地说，它提供预防，治疗或改善炎症，自身免疫性疾病，中枢性疾病，缺血性疾病中的再灌注损伤，器官移植或器官手术后的预后恶化或PTCA后的再狭窄的药剂。 更具体地说，它提供预防，治疗或改善关节炎，皮炎，肾炎，肝炎，肾衰竭，膀胱炎，前列腺炎，尿道炎，溃疡性结肠炎，克罗恩病，慢性类风湿性关节炎，骨关节炎，特应性皮炎，接触性皮炎，牛皮癣，皮肤 溃疡或褥疮。

公开(公告)号：EP1671655A1

公开(公告)日：2006-06-21

申请号：EP04772726.8

申请日：2004-08-27

申请人： AnGes MG, Inc.

发明人： KUNUGIZA, Yasuo ,  TOMITA, Naruya ,  YOSHIKAWA, Hideki ,  TANIYAMA, Yoshiaki ,  TAMAI, Katsuto ,  MORISHITA, Ryuichi

IPC分类号： A61K48/00 ,  A61K38/16 ,  A61K31/7088 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61K9/08

CPC分类号： A61K9/0024 ,  A61K31/7088 ,  A61K48/0075

摘要： The present invention provides highly useful clinical methods for treating skin disorders, particularly intractable skin disorders. Specifically, the methods comprise injecting/subcutaneously introducing a 10 µg to 10 mg dose of a polynucleotide, such as a DNA, oligonucleotide, RNA, siRNA, and antisense, around a lesion associated with a skin disorder, such as a wound, cutaneous ulcer, or psoriasis, using a needleless syringe that injects a pharmaceutical liquid by using gas pressure or the elastic force of an elastic member to drive a piston.

摘要翻译： 本发明提供用于治疗皮肤病症，特别是顽固性皮肤病症的非常有用的临床方法。 具体地说，该方法包括将注射/皮下注射10μg至10mg剂量的多核苷酸，例如DNA，寡核苷酸，RNA，siRNA和反义，在与皮肤病例如伤口，皮肤溃疡相关的病变周围 或银屑病，使用无针注射器，其通过使用气体压力或弹性构件的弹力来驱动活塞而喷射药液。

公开(公告)号：EP1647292A1

公开(公告)日：2006-04-19

申请号：EP04730727.7

申请日：2004-04-30

申请人： Morishita, Ryuichi ,  AnGes MG, Inc. ,  SHIMADZU CORPORATION

发明人： MORISHITA, Ryuichi ,  TOMITA, Naruya ,  KUNUGIZA, Yasuo ,  TANIYAMA, Yoshiaki ,  KOIKE, Hiromi ,  UDAGAWA, Haruhide c/o Shimadzu Corporation ,  KIMURA, Tatsuo c/o Shimadzu Corporation

IPC分类号： A61M5/30 ,  C12N15/00

CPC分类号： A61M5/30 ,  A61K38/1833 ,  A61K48/00

摘要： The present invention provides a needleless syringe having, accommodated therein, a pharmaceutical preparation containing genes and/or analogues thereof. A needleless syringe comprising: a medical agent chamber 22 having one or multiple nozzle bore(s) 25 and accommodated with a medical agent L, and a syringe main body 12 being provided with pressure application means 32 to apply pressure on the medical agent L toward a direction of the nozzle bore (s) 25 and effect emission of the medical agent L through the nozzle bore (s) 25, wherein the medical agent L is a pharmaceutical preparation containing genes and/or analogues thereof. Examples of the medical agent L include pharmaceutical preparation containing HGF gene and pharmaceutical preparation containing NF-κB decoy oligonucleotide.

摘要翻译： 本发明提供了一种无针注射器，其中容纳有含有其基因和/或类似物的药物制剂。 一种无针注射器，包括：具有一个或多个喷嘴孔25并容纳有药剂L的药剂处理室22，以及注射器主体12，其设有施加压力的压力施加装置32，以向药剂L施加压力 喷嘴孔25的方向并且通过喷嘴孔25发射药剂L，其中药剂L是含有其基因和/或类似物的药物制剂。 药剂L的实例包括含有HGF基因的药物制剂和含有NF-κB诱饵寡核苷酸的药物制剂。

公开(公告)号：EP1669450B1

公开(公告)日：2011-11-09

申请号：EP04788459.8

申请日：2004-09-29

申请人： AnGes MG, Inc.

发明人： KUNUGIZA, Yasuo ,  TOMITA, Naruya ,  HASHIMOTO, Hideo ,  YOSHIKAWA, Hideki ,  MORISHITA, Ryuichi

IPC分类号： C12N15/11 ,  A61K48/00 ,  A61K31/713 ,  A61P37/00 ,  A61P17/00 ,  A61P9/00 ,  A61P13/10 ,  A61P13/12 ,  A61P13/08 ,  A61P13/02 ,  A61P1/04

CPC分类号： A61K31/713 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/51

摘要： It is intended to provide an oligonucleotide and a drug to thereby solve problems occurring in existing oigonucleotides, for example, being unstable because of being opened at both ends, and showing toxicity caused by phosphorothioate when modified with phosphorothioate (S-modification) to elevate the stability to digesting enzymes. More specifically speaking, a staple type oligonucleotide and a drug containing the same as the active ingredient. More particularly, a transcriptional factor inhibitor, an antisense oligonucleotide or an siRNA, in greater detail, a drug for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischemic diseases, worsened prognosis after organ transplantation or organ operation or restenosis after PTCA. Still specifically speaking, a drug for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn’s disease, rheumatoid arthritis or arthritis deformans, atopic dermatitis, contact dermatitis, prosiasis, skin ulcer or bed sore.